BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Inyx, Inc. Completes Acquisition Of Aventis Pharmaceuticals Puerto Rico Inc.


10/19/2005 5:13:11 PM

NEW YORK, March 31 /PRNewswire-FirstCall/ -- Inyx, Inc. (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, announced today that it has completed its acquisition of certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc. from Aventis Pharmaceuticals, Inc., a member of the sanofi-aventis Group . The approximate $19.7 million acquisition price was financed through non-dilutive, asset-based funding provided by Westernbank Business Credit Division of Westernbank Puerto Rico (see separate press release also issued today on the asset-based financing secured by Inyx).

Jack Kachkar, M.D., Chairman and CEO of Inyx, said, "This acquisition is truly a 'transforming event' for Inyx. We have acquired materially valuable assets and several significant new business contracts and strategic new customers and partnering relationships."

The operations in Manati, Puerto Rico consist of a high-calibre pharmaceuticals development and production center that provides Inyx with a base in the United States to complement Inyx's present facilities located in the United Kingdom. Inyx also gains favorable tax incentives, including a corporate income tax rate of 2%-7% for 15 years from its operations out of Puerto Rico.

"Puerto Rico provides Inyx with a gateway on this side of the Atlantic to best serve the markets in the U.S., Canada, Latin and South America. In addition, Puerto Rico is home to 23 other leading pharmaceuticals companies, a captive marketplace for Inyx to cultivate, both for new contract clients and for strategic marketing partners of Inyx' own proprietary products," Dr. Kachkar noted.

The Manati complex consists of five buildings totaling about 140,000 square feet and extends over 9.5 acres, located in north central Puerto Rico about 30 miles outside of San Juan. Inyx is employing approximately 140 people to start in Puerto Rico. The operations in Puerto Rico are under Inyx's newly formed, wholly owned subsidiary, Inyx USA, Ltd.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with aerosol drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services to the international healthcare market. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners, which include some of the largest pharmaceutical companies. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd.; INyX Pharma Limited, with R&D and production facilities located near Manchester, England, which serves global markets in Europe and the Middle East; Inyx Canada, Inc. based in Toronto, provides business development and support services; Inyx, Inc.'s corporate offices are in New York City. Inyx now has total approximately 255 employees, about 100 of whom are based in England at its 60,000 square foot production center and 30,000 square foot development and administrative facilities. For more information, please visit: http://www.inyxinc.com/.

Safe Harbor

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

For more information, please contact: Jay M. Green, Executive Vice President Inyx, Inc. jgreen@inyxinc.com Matt Tidwell, Senior Manager, Industrial Affairs Communications Aventis Pharmaceuticals, Inc. matthew.tidwell@aventis.com

Inyx, Inc.

CONTACT: Jay M. Green, Executive Vice President of Inyx, Inc.,jgreen@inyxinc.com; or Matt Tidwell, Senior Manager, Industrial AffairsCommunications of Aventis Pharmaceuticals, Inc., matthew.tidwell@aventis.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->